Literature DB >> 12571644

Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation.

E Vigne1, J-F Dedieu, A Brie, A Gillardeaux, D Briot, K Benihoud, M Latta-Mahieu, P Saulnier, M Perricaudet, P Yeh.   

Abstract

The development of genetically modified adenoviral vectors capable of specifically transducing a given cell population requires the addition and functional presentation of particular tropism determinants within the virus capsid, together with the abrogation of the molecular determinants that dictate their natural tropism in vivo. The human adenovirus serotype 5 (Ad5) first attaches to the cell surface following high-affinity binding of the C-terminal knob of the fiber capsid protein to the coxsackie and adenovirus receptor (CAR). Here we have assessed whether genetic shortening of the fiber shaft (virus BS1), or replacing the Ad5 fiber shaft and knob with their Ad3 counterparts (virus DB6), could cripple this interaction in vitro and in vivo. A 10-fold decrease in the binding of the modified capsids to soluble CAR was evidenced, which correlated with a similar reduction of their ability to transduce CAR-positive cells in vitro. The ability of BS1 to interact with cellular integrins was also impaired, suggesting that the penton base and the short-shafted fiber when embedded in the capsid preclude each other from efficiently interacting with their cognate cell surface receptors (CAR and integrins respectively). BS1 and DB6 intravenous injections in mice further supported a profound impairment of the ability of the capsid-modified viruses to transduce the liver as demonstrated by a 10-fold reduction of intracellular viral DNA and transgene expression. Interestingly enough, the host humoral response was also specifically weakened in BS1- and DB6-inoculated animals. Taken together, these observations indicate that (i) fiber shortening and (ii) pseudo-typing of Ad5-based vectors with the shaft and knob from non-CAR-binding serotypes constitute two promising strategies to successfully attenuate their native tropism in vitro and most importantly in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12571644     DOI: 10.1038/sj.gt.3301845

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

1.  Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.

Authors:  Naoya Koizumi; Hiroyuki Mizuguchi; Fuminori Sakurai; Teruhide Yamaguchi; Yoshiteru Watanabe; Takao Hayakawa
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop.

Authors:  J Woraratanadharm; S Rubinchik; H Yu; F Fan; S M Morrow; J Y Dong
Journal:  Gene Ther       Date:  2004-09       Impact factor: 5.250

4.  Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs.

Authors:  Dmitry M Shayakhmetov; Andrea M Eberly; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 5.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

Review 6.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

7.  Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.

Authors:  Nelson C Di Paolo; Nico van Rooijen; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

Review 8.  Current developments in adenovirus-based cancer gene therapy.

Authors:  Daniel T Rein; M Breidenbach; David T Curiel
Journal:  Future Oncol       Date:  2006-02       Impact factor: 3.404

9.  Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expression.

Authors:  Jan Woraratanadharm; Semyon Rubinchik; Hong Yu; John Y Dong
Journal:  BMC Biotechnol       Date:  2007-02-12       Impact factor: 2.563

10.  Protein crystals in Adenovirus type 5-infected cells: requirements for intranuclear crystallogenesis, structural and functional analysis.

Authors:  Laure Franqueville; Petra Henning; Maria Magnusson; Emmanuelle Vigne; Guy Schoehn; Maria E Blair-Zajdel; Nagy Habib; Leif Lindholm; G Eric Blair; Saw See Hong; Pierre Boulanger
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.